Life Sciences

Worcester-based nanomedicine firm Eascra Biotech has expanded its footprint at Massachusetts Biomedical Initiatives, moving into a space more than three times the size of its initial lab.

Lifeward has announced the departure of its CEO and CFO, as the Hudson medical device manufacturer said its current cash resources are insufficient to fund planned operations over the next year.

The firm is looking to manufacture its drug delivery materials in a microgravity environment.

Worcester County’s increase came as the state’s biopharma employment levels fell 3.1% in 2025, the first annual decline in more than two decades.

After being sold from one private equity firm to another in September, Hopkinton-based Isto Biologics has acquired a fellow biotech firm focused on bonehealing.

Marlborough-based Boston Scientific Corp. is launching a three-year, $800-million restructuring plan that will include layoffs.

Rentschler Biopharma, which has its U.S. headquarters in Milford, has selected a 25-year veteran of contract development and manufacturing organizations as its next CEO.

WuXi Biologics has fully resumed construction on its Worcester manufacturing facility and now expects the $300-million life sciences facility to be complete in 2028.

The company's sponge‑like device helps a torn ACL grow back together using a patient’s own blood, allowing the ligament to heal itself.

Chiesi is now in control of KalVista’s 32,110-square-foot headquarters and lab space at 200 Crossing Boulevard in Framingham.